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http://www.biomedcentral.com/1756-0500/7/278RESEARCH ARTICLE Open AccessDNA methylation signatures in cord blood
associated with maternal gestational weight gain:
results from the ALSPAC cohort
Eva Morales1,2,3,4, Alexandra Groom5,6, Debbie A Lawlor5,6 and Caroline L Relton1,5,6*Abstract
Background: Epigenetic changes could mediate the association of maternal pre-pregnancy body mass index (BMI)
and gestational weight gain (GWG) with adverse offspring outcomes. However, studies in humans are lacking. Here,
we examined the association of maternal pre-pregnancy BMI and GWG in different periods of pregnancy with
cytosine-guanine (CpG) dinucleotide site methylation differences in newborn cord blood DNA from 88 participants
in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort using the Illumina GoldenGate Panel I.
Pyrosequencing was used for validation of the top associated locus and for replication in 170 non-overlapping
mother-offspring pairs from the ALSPAC cohort.
Results: After correction for multiple testing greater GWG in early pregnancy (between 0 to 18 weeks of gestation)
was associated with increased DNA methylation levels in four CpG sites at MMP7, KCNK4, TRPM5 and NFKB1 genes
(difference in methylation >5% per 400 g/week greater GWG) (q values 0.023 -0.065). Pre-pregnancy BMI and GWG
in mid- or late pregnancy were not associated with differential DNA methylation at any CpG site. Pyrosequencing
showed that greater GWG in early pregnancy was associated with increased DNA methylation levels at the top
associated CpG site at MMP7, although association did not reach statistical significance (p = 0.302). Greater GWG in
mid- (p = 0.167) and late-pregnancy (p = 0.037) were also associated with increased DNA methylation levels at the
MMP7 CpG site. In addition, newborns of mothers who exceeded the IoM-recommended GWG had higher DNA
methylation levels at the MMP7 CpG site than those of mothers with IoM-recommended GWG (p = 0.080). We failed
to replicate findings.
Conclusions: Greater GWG in early pregnancy was associated with increased methylation at CpG sites at MMP7,
KCNK4, TRPM5 and NFKB1 genes in offspring cord blood DNA. The specific association of GWG in early pregnancy
with the top associated CpG site at MMP7 was not validated using Pyrosequencing and it did not replicate.
However, given the potential functional relevancy of the four identified loci, we advocate further exploration of
them in larger studies.
Keywords: DNA methylation, Epigenetics, Gestational weight gainBackground
Greater maternal pre- or early- pregnancy body mass
index (BMI) and gestational weight gain (GWG) have
been shown to be associated with health outcomes in
offspring, including increased birth weight [1,2], im-
paired cognitive development and behavioral problems* Correspondence: caroline.relton@ncl.ac.uk
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unless otherwise stated.[3,4], increased adiposity and adverse cardiometabolic
traits [5-13]. The biological mechanisms underpinning
these associations remain elusive. Potential mechanisms
may include genetic factors, shared postnatal environ-
ment, as well as intrauterine metabolic programming,
possibly through epigenetic mechanisms [13,14]. With
respect to potential intrauterine mechanisms the main
exposure is greater maternal adiposity during pregnancy,
and thus one might expect a specific association of
GWG in early pregnancy, when the contribution of ma-
ternal fat deposition is greater than that of fetal weightl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Morales et al. BMC Research Notes 2014, 7:278 Page 2 of 10
http://www.biomedcentral.com/1756-0500/7/278or other GWG contributions in later periods, and little
or no association of GWG in mid or later pregnancy
with offspring outcomes [8,14]. In relation to offspring
adiposity and cardiometabolic outcomes results from the
cohort used in this study support this expectation [8].
To our knowledge only one study in humans has ex-
amined the association of maternal pregnancy adiposity
with offspring DNA methylation patterns. In that study,
cord blood white cell DNA methylation was compared
between 25 offspring born before their mothers had
undergone bypass surgery for severe obesity with 25
matched siblings born after marked weight loss by their
mothers following bypass surgery, using the Illumina
HumanMethylation450 BeadChip array [15,16]. Altered
methylation and gene expression profiles of genes with
known glucose-metabolic and inflammatory related
functions were identified between those offspring born
after their mothers surgery compared to those born
before [15,16]. Recently a study conducted in African-
American population has reported maternal pre-
pregnancy BMI to be associated with offspring cord blood
DNA methylation levels of the CpG sites in genes involved
in a broad array of chronic diseases including cancer and
cardiovascular diseases [17]. However, whether similar
associations would be found between maternal GWG in
humans is currently unknown. Nonetheless evidence from
animal models strongly supports an effect of greater
maternal pregnancy adiposity on offspring epigenome. For
example, gene expression and DNA methylation patterns
at loci involved in adipocyte commitment have been
shown to be perturbed in rodent models of maternal
obesity and overfeeding during pregnancy [18,19].
We hypothesize that maternal pre-pregnancy BMI and
GWG, specifically in early pregnancy, could influence
risk of adverse health outcomes in offspring by inducing
epigenetic changes. Thus, we aimed to examine whether
maternal pre-pregnancy BMI and GWG in different
periods of pregnancy were associated with epigenetic
marks in newborns, in terms of gene-specific cord blood
DNA methylation, and to compare the early pregnancy
GWG associations with mid- and late-pregnancy GWG
to test whether there was any evidence of specific early
pregnancy associations. Our analyses were undertaking
in a discovery sample and then in a replication sample,
both taken from a large, longitudinal UK cohort of
mothers and their offspring.
Method
Discovery and validation study
Study population
Data were available from participants in the Avon Longi-
tudinal Study of Parents and Children (ALSPAC), a pro-
spective, population-based mother-child cohort study
that recruited over 14 000 pregnant women resident inAvon, UK, between 1991 and 1992 (http://www.alspac.
bristol.ac.uk) [20,21]. A subset of 96 children from the
ALSPAC cohort was selected for analysis of DNA
methylation at Cytosine-Guanine (CpG) dinucleotide
sites in DNA extracted from cord blood samples. Sam-
ples used in this study had been analyzed as part of a
study of maternal exposure to paracetamol, as described
in previous literature [22], and were broadly representa-
tive of the ASPAC cohort. Of the 96 mother-offspring
pairs with methylation data available, complete data on
maternal pre-pregnancy BMI, GWG and potential con-
founders were available for 88 pairs.
Maternal pre-pregnancy BMI and GWG
Six trained research midwives abstracted data from ob-
stetric medical records for the entire ALSPAC cohort.
Obstetric data abstractions included every measurement
of weight entered into the medical records and the
corresponding gestational age and date. All pregnancy
weight measurements (median number of repeat mea-
surements per woman, 10; range, 1, 17) were used to
develop a linear spline multilevel model (with 2 levels:
woman and measurement occasion) relating gestational
age to weight. Using the entire cohort of women with
term pregnancies (≥37 weeks of gestation) fractional
polynomial curves were fitted to the data to obtain the
average shape of the trajectories of GWG with gesta-
tional age (for full statistical methodological details see
[8]). These were used to determine the approximate
positions of knots (indicating changes in slope) in linear
spline random effects models with GWG as outcome
and gestational age in weeks as the exposure. The knots
produced from the modelling resulted in 4 variables:
Pre-pregnancy weight (kg), change in weight between 0
and 18 weeks (kg/week), change in weight between 19
and 28 weeks (kg/week), and change in weight between
29 weeks and birth (kg/week). Pre-pregnancy body mass
index (BMI) (kg/m2) was based on the mother’s self-
reported weight before pregnancy and maternal report
of height at their first questionnaire assessment (~12-18
weeks gestation) (results were identical for predicted
pre-pregnancy weight with the use of multilevel models)
[8]. To allocate women to Institute of Medicine (IoM)
GWG categories (less than recommended, recommended,
or more than recommended), we used weight measure-
ments from the obstetric notes and subtracted the first
from the last weight measurement in pregnancy to derive
absolute weight gain [23].
Cord blood DNA methylation analysis using Illumina
Golden Gate
DNA extracted from cord blood was used for DNA
methylation analysis. Site-specific CpG methylation was
analysed using bisulphite treated DNA (EZ-96 DNA
Morales et al. BMC Research Notes 2014, 7:278 Page 3 of 10
http://www.biomedcentral.com/1756-0500/7/278Methylation Gold Kit, Zymo Research) using the the
GoldenGate Cancer Panel I Array (Illumina Inc, USA)
and the GoldenGate Assay Kit with UDG on the Sentrix
Universal-96 Array matrix v7A. This panel spans 1,505
CpG sites selected from 807 genes. Arrays were imaged
using a BeadArray scanner and image processing and
intensity data extracted using Illumina BeadStudio v3.2,
methylation module v3.2.5 custom software. Methylation
levels (beta values, β) at a given CpG site were estimated
as the ratio of signal intensity of the methylated alleles
to the sum of methylated and unmethylated intensity
signals of the alleles: β =M/(U +M), where M was the
fluorescence level of the methylation probe and U was
the fluorescence level of the unmethylated probe. The
beta values vary from 0 (no methylation) to 1 (100%
methylation). Samples were run across four different
PCR plates.
Other variables
Based on previous knowledge, the following were con-
sidered a priori potential confounding factors because
of their possible associations with either maternal pre-
pregnancy BMI or GWG and DNA methylation levels:
child’s sex and ethnic background, mode of delivery,
maternal age at child’s birth, parity, maternal smoking in
pregnancy and occupation. Child’s sex, maternal age,
parity (0 or 1+) and mode of delivery (cesarean or vagi-
nal delivery), and child’s ethnic background (white or
non-white) were obtained from the obstetric records.
Maternal smoking and occupational (of both the mother
and her partner) were reported by the mother in a study
questionnaire administered at mean 18 weeks gestation;
with data on smoking also reported in subsequent
questionnaires administered during pregnancy. Maternal
smoking in pregnancy was categorized as no versus yes.
Highest parental occupation was used to allocate the
children to family social class groups according to the
1991 British Office of Population and Census Statistics
classification [24] (with the higher class of either parent
where these differed being used); this was collapsed into
a binary variable of manual versus non-manual in this
study.
Validation study
A PyroMark MD Pyrosequencing System (Qiagen) was
used for the validation of the top associated locus
(MMP7_E59). This quantifies DNA methylation in a
sequencing-by-synthesis manner providing precise methy-
lation levels of several CpG positions in close proximity
[25]. The DNA segment harboring the region of MMP7
amplified for this purpose and analyzed consisted of the
sequence 5′- AGGCTGAGAAGCTATATAAATTTCTG
CAGTCACTAGCAGAAAACACCAAATCAACCATAG
GTCCAAGAACAATTGTCTCTGGACGGCAGCTATGCGACTCACCGTGCTGTGTGCTGTGTGCCTGCTGC
CTGGCAGCCTGGCCCTGCCGCTGCCTCAGGAGGC
GGGAGGCATGAGTGAGCTACAGTGGGAAC-3′. As
indicated in italics, we analyzed three CpG sites overall.
The one referring to CpG probe site MMP7_E59 is
highlighted in bold. The forward PCR and reverse PCR,
and sequencing primers are AGGTTGAGAAGTTATA
TAAA, ATTCCCACTATAACTCACT, and AATTAAT
TATAGGTTTAAGA, respectively. Briefly, bisulfite con-
version of genomic DNA was performed using EZ DNA
Methylation Gold™ kit (Zymo Research) following the
manufacturer’s protocol. Quantitative bisulphite Pyrose-
quencing (Qiagen, UK) with Pyro Q-CpG™ Software
(version 1.0.6.) was subsequently used to determine the
percentage methylation at individual CpG sites. 1ug of
DNA was bisulfite modified. Bisulfite treated DNA was
added to the first PCR reaction with 12.5 μl Hot Star
Taq mastermix (Qiagen) and optimised primer concen-
trations and annealing temperature. PCR cycling condi-
tions were: 95 degrees C for 15 min, 50 cycles of 95 for
15 secs, 45 degrees C for 30secs, 72 for 15 secs, 72 for
5 min, and 4 for hold/storage. Assays were assessed
for amplification bias and reliability as described previ-
ously [26,27]. Zero and 100% in vitro methylated con-
trols were run routinely alongside samples as internal
controls, as well as, negative controls consisting of DNA
free wells. Zero and 100% in vitro methylated internal
controls showed good correlation (R2 = 0.99). Two inde-
pendent replicates per sample were processed on separ-
ate runs, giving good correlation (R2 between 0.658 and
0.847).
Replication study
The same Pyrosequencing assay used during the valid-
ation study of the top associated locus (MMP7_E59) was
used to analyze 192 non-overlapping mother-offspring
pairs randomly selected from the 2,183 ALSPAC cohort
participants with cord blood DNA available and who
were not included in the discovery study. Of these 192
pairs 170 (88%) could be successfully characterized.
Statistical analysis
In the discovery study mixed linear regression models
were fitted to estimate the association of pre-pregnancy
BMI and GWG in different periods of pregnancy with
DNA methylation in offspring cord blood, regressing the
methylation status at each CpG site quantified by the
Illumina beta value (dependent variable) against mater-
nal pre-pregnancy BMI or GWG (independent vari-
ables). Maternal pre-pregnancy BMI and GWG were
scaled to be clinically meaningful, examining the vari-
ation in CpG site DNA methylation per 1 SD change of
maternal pre-pregnancy BMI and per 400 g gain per
week of gestation for GWG [8]. Final models were
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included as fixed coefficients and a PCR plate effect as a
random batch coefficient. Allowance for other possible
confounding variables such as child’s ethnic background,
mode of delivery, parity, maternal smoking in pregnancy
and occupation did not materially alter the estimates.
Results were summarized as means and standard errors.
Lists of CpG sites with differential methylation in beta
values (difference >0.05) at a p value < 0.01– a pragmatic
threshold for selecting CpG sites for further study –
were generated for maternal pre-pregnancy BMI, and
GWG in early (from 0 to 18 weeks of pregnancy), mid
(from 19 to 28 weeks of pregnancy), and late pregnancy
(from 29 weeks of pregnancy onwards). False discovery
rate correction for multiple testing was performed and
q-values were computed by the ‘qvalue’ package in the R
statistical package version 2.9.1 (R Foundation for Statis-
tical Computing, Vienna, Austria). A false discovery rate
q-value of <0.1 was considered statistically significant.
In the validation and replication analyses based on
Pyrosequencing, CpG site methylation levels were also
analyzed by mixed linear regression models adjusted for
child’s sex and maternal age at child’s birth as fixed coef-
ficient and PCR plate as a random batch effect as out-
lined above.
Ethical approval
Ethical approval for all aspects of data collection was
obtained from the ALSPAC Law and Ethics Committee
and the Local Research Ethics Committee in accordance
with the guidelines of The Declaration of Helsinki. Writ-
ten informed consent was obtained for all participants in
the study.
Results
Discovery study: illumina golden gate
The discovery study population included 88 mother-
offspring pairs. Participants were unrelated newborns
born at term and 50% male. Mean (sd) maternal age at
birth was 30.2 (3.5) years. In comparison with eligible
participants for the present study, mothers included in
the discovery study were older, and were less likely over-
weight or obese before pregnancy, but did not differ in
GWG (Table 1).
Maternal pre-pregnancy BMI was not found to be as-
sociated with differentially methylated DNA at any CpG
site in offspring cord blood (Additional file 1: Table S1).
Early pregnancy GWG was associated with differential
DNA methylation at 44 CpGs sites in offspring cord
blood (p value < 0.01) (Table 2). Six out of these 44 CpG
sites (located in 5 genes) had a difference in the Illumina
beta value of >0.05 (MMP7_ E59 p value = 1.55E-05;
KCNK4_P171 p value = 4.57E-05; TRPM5_E87 p value =
0.0003; NFKB1_P496 p value = 0.0002; TRPM5_P721p value = 0.0017; and ABCC2_E16 p value = 0.0018); of
these, 4 CpG sites remained robust to correction for mul-
tiple comparison testing: MMP7_E59 (q value = 0.023),
KNCK4_P171 (q value = 0.034), TRPM5_E87 (q value =
0.065), and NFKB1_P496 (q value = 0.065) (Table 2).
Greater GWG in mid pregnancy was associated with
changes in methylation (difference in beta value >0.05)
at one CpG site at MAP3K1_E81 (p value = 0.003);
although it did not remain statistically significant after
correction for multiple comparison testing (q value =
0.917) (Additional file 1: Table S2). GWG in late preg-
nancy was not associated with differential DNA methyla-
tion at any CpG site (all differences in beta values <0.05)
(Additional file 1: Table S3).
Pyrosequencing validation study
The association of early pregnancy GWG with differen-
tial methylation at the top associated CpG site at MMP7
was validated by reanalyzing CpG site MMP7_E59 in the
discovery study using Pyrosequencing. The methylation
levels assayed using the GoldenGate platform did not
correlate with Pyrosequenced values (R-squared = 0.005;
p value = 0.508).
The two adjacent CpG sites covered in the Pyrose-
quenced amplicon were highly correlated with
MMP7_E59 and with each other (Pearson’s correlation
coefficients all >0.87; all p < 0.0001). In agreement with
the discovery findings, Pyrosequencing results showed
that greater GWG in early pregnancy tended to be asso-
ciated with higher methylation at the MMP7_E59 CpG
site, although the association did not reach statistical
significance (p value = 0.302 (Table 3). Moreover, greater
GWG in mid- and late pregnancy were associated
with increased methylation at the MMP7_E59 CpG site
(p values = 0.167 and 0.037, respectively) (Table 3). In
addition, newborns of mothers that gained greater than
IoM recommended weight showed higher methylation
levels at the MMP7_E59 CpG site compared to those
newborns of mothers with IoM recommended weight
(p value = 0.080) (Table 3). Maternal GWG and IoM
recommended weight categories showed similar associa-
tions with DNA methylation levels at the other 2 CpG
sites evaluated at MMP7.
Replication study
The replication study population included 170 non-
overlapping mother-offspring pairs from the ALSPAC
cohort. Participants were unrelated newborns born at
term and 51% male. Mean (sd) maternal age at birth was
28.7 (4.4) years. Compared with the discovery study
sample those included in the replication study have
younger mothers that were more likely overweight or
obese before pregnancy, but did not differ in GWG
(Table 1). Pyrosequencing results showed no association
Table 1 Characteristics of the study populations from the ALSPAC cohort
Discovery & Validation sample (n = 88)† Replication sample (n = 170) Rest of eligible (n = 1991)§
Child’s sex, male (%) 51.1 50.6 49.5
Age of mother at birth, mean (sd) 30.6 (3.3) 28.7 (4.4) 27.4 (5.1)
Maternal pre-pregnancy BMI (kg/m2)
Mean (sd) 22.2 (3.05) 23.8 (4.1) 23.1 (3.9)
Normal, 18.5-24.9, (%) 85.9 68.6 73.6
Underweight, < 18.5, (%) 1.2 2.4 4.8
Overweight, 25.0-29.9, (%) 10.6 20.7 15.5
Obese, ≥ 30, (%) 2.4 8.3 6.1
GWG (kg/wk)
0 to 18 weeks
Mean (sd) 0.32 (0.17) 0.31 (0.18) 0.30 (0.18)
Median 0.33 0.32 0.31
Min, Max −0.33, 0.83 −0.22, 0.79 −0.64, 1.31
19-28 weeks
Mean (sd) 0.55 (0.17) 0.54 (0.16) 0.53 (0.18)
Median 0.55 0.53 0.53
Min, Max 0.22, 1.00 0.14, 0.96 −0.18, 1.45
29 weeks onwards
Mean (sd) 0.49 (0.18) 0.47 (0.20) 0.46 (0.21)
Median 0.47 0.45 0.45
Min, Max −0.02, 0.95 0.03, 1.04 −0.54, 1.22
IoM categories, (%)
Recommended 36.6 37.3 36.1
Less than recommended 34.1 31.9 35.8
More than recommended 29.3 30.8 28.1
†4 subjects initially included in the discovery study (n = 88) failed in the validation study.
§Participants of the ALSPAC cohort with available cord blood DNA.
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of pregnancy with differential methylation at MMP7
CpG sites (all p values >0.1) (Table 4).
Discussion
This study examined the association of maternal pre-
pregnancy BMI and GWG in different periods of preg-
nancy with gene-specific DNA methylation changes in
offspring cord blood. Screening analysis using the Illu-
mina GoldenGate Panel I in a discovery sample of 88
mother-offspring pairs showed greater GWG in early
pregnancy (from 0 to 18 weeks) to be associated with
differential methylation at 4 CpG sites at MMP7,
KCNK4, TRPM5 and NFKB1 genes after correcting for
multiple statistical testing. Of these four loci we under-
took validation and replication using Pyrosequencing of
the top associated locus at MMP7. Results of the valid-
ation study did not support evidence for an association
with early pregnancy GWG with differential methylation
at this locus, but was suggestive of an association withGWG in later pregnancy and for exceeded IoM recom-
mended GWG. However, we failed to replicate these
findings for this one locus in 170 non-overlapping
mother-offspring pairs of the ALSPAC cohort.
The specific association of early pregnancy GWG with
differential methylation at four loci is notable, since early
GWG is more likely to reflect maternal fat deposition
than later GWG (which will be influenced more by fetal
growth) [13], and so this specificity, together with the
potential functional roles of these loci (see below), might
support these findings as being important in develop-
mental overnutrition. However, we were only able to
undertake validation and replication studies for one, the
most strongly associated loci (MMP7) and the specific
early GWG association with differential methylation at
that locus did not validate or replicate.
Our more significant finding in the discovery study
was increased methylation of CpG sites at MMP7 gene
in relation to greater GWG. Matrix metalloproteinases
(MMPs) comprise a large family of structurally related
Table 2 List of CpG sites with differential methylation at a p value < 0.01 in newborn cord blood DNA per 400 g of
weight gain/week in early pregnancy (from 0 to 18 weeks), the ALSPAC cohort (n = 88)
Chra Gene name CpG site Positionb Coefc. (se) p value q value
11 Matrix metallopeptidase 7 MMP7_E59 101906629 0.072 (0.016) 1.55E-05 0.023
11 Potassium channel, subfamily K, member 4 KCNK4_P171 63815280 0.060 (0.014) 4.57E-05 0.034
19 Janus kinase 3 JAK3_P1075 17820875 0.034 (0.008) 7.13E-05 0.036
11 Transient receptor potential cation channel,
subfamily M, member 5
TRPM5_E87 2400764 0.072 (0.020) 0.0003 0.065
12 Protein tyrosine phosphatase, non-receptor type 6 PTPN6_E171 6926172 0.042 (0.011) 0.0003 0.065
4 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
NFKB1_P496 103641022 0.058 (0.016) 0.0002 0.065
1 Absent in melanoma 2 AIM2_E208 157313063 0.015 (0.004) 0.0003 0.065
17 Ecotropic viral integration site 2A EVI2A_E420 26672423 0.039 (0.010) 0.0002 0.065
17 Septin 9 SEPT9_P58 72827686 0.034 (0.010) 0.0005 0.077
15 Interleukin 16 IL16_P93 79262162 0.037 (0.011) 0.0006 0.077
9 PALM2-AKAP2 protein PALM2_AKAP2_P183 111582227 0.025 (0.007) 0.0005 0.077
20 DNA (cytosine-5-)-methyltransferase 3 beta DNMT3B_P352 30813500 0.040 (0.012) 0.0005 0.077
13 5-hydroxytryptamine (serotonin) receptor 2A HTR2A_E10 46368166 0.011 (0.003) 0.0008 0.096
6 RAB32, member RAS oncogene family RAB32_P493 146906028 0.038 (0.011) 0.0009 0.098
22 Breakpoint cluster region (BCR) BCR_P422 21852130 0.024 (0.007) 0.0010 0.103
9 Transmembrane protein with EGF-like and two
follistatin-like domains 1
TMEFF1_P234 102275304 0.042 (0.013) 0.0016 0.146
11 Transient receptor potential cation channel,
subfamily M, member 5
TRPM5_P721 2401572 0.053 (0.017) 0.0017 0.148
10 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2_E16 101532577 0.078 (0.025) 0.0018 0.148
12 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS_E82 25295039 0.042 (0.014) 0.0021 0.155
11 Tumor susceptibility gene 101 TSG101_P139 18505204 0.045 (0.015) 0.0022 0.155
11 Solute carrier family 22 (organic cation transporter),
member 18
SLC22A18_P216 2877311 0.032 (0.011) 0.0021 0.155
20 v-src sarcoma (Schmidt-Ruppin A-2) viral
oncogene homolog (avian)
SRC_P164 35406338 0.051 (0.017) 0.0027 0.177
6 Major histocompatibility complex, class II, DO beta HLA_DOB_P1114 32893876 0.014 (0.004) 0.0027 0.177
X Biglycan BGN_P333 152413272 0.027 (0.009) 0.0030 0.181
2 Interleukin 1, beta IL1B_P829 113311656 0.029 (0.009) 0.0030 0.181
11 Cathepsin D (lysosomal aspartyl peptidase) CTSD_P726 1742524 0.033 (0.011) 0.0034 0.192
7 Carboxypeptidase A4 CPA4_P961 129719269 0.020 (0.007) 0.0035 0.192
22 Breakpoint cluster region (BCR) BCR_P346 21852206 0.021 (0.007) 0.0036 0.192
16 PYD and CARD domain containing PYCARD_E87 31121665 0.023 (0.008) 0.0038 0.192
17 Homeo box B2 HOXB2_P99 43977490 0.040 (0.014) 0.0038 0.192
17 v-crk sarcoma virus CT10 oncogene homolog (avian) CRK_P721 1307015 0.043 (0.015) 0.0039 0.192
22 Seizure related 6 homolog (mouse)-like SEZ6L_P299 24895181 0.031 (0.011) 0.0044 0.208
19 Kallikrein 11 KLK11_P103 56223205 0.022 (0.008) 0.0046 0.210
X ELK1, member of ETS oncogene family ELK1_E156 47394808 0.025 (0.009) 0.0058 0.255
2 CDC-like kinase 1 CLK1_P538 201438205 0.036 (0.013) 0.0064 0.263
6 Solute carrier family 22 (organic cation transporter), member 2 SLC22A2_P109 160600058 0.021 (0.008) 0.0064 0.263
19 Apolipoprotein C-II APOC2_P377 50140706 0.015 (0.006) 0.0067 0.263
X Dyskeratosis congenita 1, dyskerin DKC1_P276 153644068 0.030 (0.011) 0.0066 0.263
20 v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene
homolog (avian)
SRC_P297 35406205 0.025 (0.009) 0.0080 0.300
Morales et al. BMC Research Notes 2014, 7:278 Page 6 of 10
http://www.biomedcentral.com/1756-0500/7/278
Table 2 List of CpG sites with differential methylation at a p value < 0.01 in newborn cord blood DNA per 400 g of
weight gain/week in early pregnancy (from 0 to 18 weeks), the ALSPAC cohort (n = 88) (Continued)
10 N-acetyltransferase 2 NAT2_P11 18293024 0.012 (0.004) 0.0079 0.300
8 PTK2 protein tyrosine kinase 2 PTK2_P735 142081249 0.022 (0.008) 0.0085 0.312
1 CD34 antigen CD34_P339 206151645 0.021 (0.008) 0.0092 0.330
4 Interleukin 8 IL8_P83 74825056 0.051 (0.019) 0.0098 0.334
11 Progesterone receptor PGR_P790 100507255 0019 (0.007) 0.0096 0.334
aChromosome. bChromosomal position based on NCBI human reference genome assembly Build 36.1.
cRegression coefficient using linear mixed models. All models adjusted for child’s sex and maternal age at child’s birth and the inclusion of a PCR plate random
batch effect.
Suffixes denote the Illumina probe identity (P = within promoter, E = within first exon).
Probes shown in bold displayed >5% difference in methylation.
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subgroups on the basis of their structure, substrate
specificity, and cellular localization and include collage-
nases, gelatinases, stromelysins, and membrane-type
(MT-MMPs) [28]. MMPs participate in processes such
as embryonic development, angiogenesis, wound repair,
reproductive cycling, and metastasis [28]. Interestingly,
MMPs are essential for proper extracellular matrix re-
modelling, a process that takes place during obesity-
mediated adipose tissue formation. Specifically, mouse
models of obesity have showed that the expression of
MMP7 is down regulated in obesity [29,30]. These find-
ings are in accordance with our results since increased
methylation of MMP7 would imply lower gene expres-
sion, which could translate into a higher risk of adiposity
in the offspring in response to an in utero obesogenic
environment. However, these associations were not rep-
licated in non-overlapping mother-offspring pairs; thus,
present results should be interpreted cautiously and
future studies are warranted to confirm the association
of greater GWG with differential methylation of MMP7.
Validation and replication studies using Pyrosequenc-
ing were not undertaken for other CpG sites that were
identified as being differentially methylated in relation to
greater GWG and located in genes KCNK4, TRPM5 and
NFKB1. However, these three identified genes may be
worthy of further exploration. KCNK4 encodes for a
potassium channel, subfamily K, member 4 known as
Trek/TRAAK channels that has been described to be
expressed in the central nervous system, modulate neur-
onal activity, brain metabolism and have a role in neuro-
protection [31,32]. Knockout animal models have shown
a role for Trek/TRAAK channels in behaviour, learning
and memory [33,34]. Interestingly, greater maternal pre-
pregnancy BMI and GWG have been shown to be asso-
ciated with offspring impaired cognition and behavioural
problems later in life, including in the ALSPAC study
[3,4]. In addition, TRPM5 encodes for a thermo-sensitive
TRP (transient receptor potential) channel that is
expressed in pancreatic β-cells and could predominantly
contribute to pancreatic functions [35]. In humans,genetic variation in TRPM5 has been reported to be
likely associated with pre-diabetic phenotypes and con-
tribute to the development of type 2 diabetes mellitus
[36]. Furthermore, TRPM5 knockout mice exhibit im-
paired glucose clearance resulting from reductions in
insulin secretion [37,38]. This evidence from animal
studies is in accordance with our results showing in-
creased methylation of TRPM5 CpG sites in relation to
greater maternal GWG; this may in turn result in lower
expression of TRPM5 and, thus, perturbed insulin me-
tabolism and increased risk of diabetes in the offspring
as it has been previously suggested [39]. Finally, NFKB1
encodes for nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1, which is responsible for acti-
vation of transcription of genes involved in immune re-
sponses, inflammation or cell proliferation [40]. Genetic
variation in NKKB1 gene has been reported to be associ-
ated with a range of immune-mediated diseases such as
atopy, asthma and related phenotypes [41], which are
also related to maternal obesity and GWG [42,43].
Therefore, DNA methylation changes at these three loci
highlighted in the screening analysis appear to have clear
functional relevance to pathways implicated in develop-
mental programming of adverse phenotypes in offspring
linked to maternal obesity and GWG and therefore
deserve further investigation.
The strengths of this study are the prospective design
and that potential confounding factors were taken into
account in the analyses. Further, we evaluated the associ-
ation of pre-pregnancy BMI and GWG in distinctive
periods of pregnancy with offspring cord blood DNA
methylation patterns. To our knowledge no previous hu-
man studies have examined these associations, yet these
maternal exposures have been shown to be related to
later offspring outcomes and it has been suggested these
associations may be mediated by epigenetic mechanisms
[8,13,14]. The ability to examine associations of different
pregnancy periods of GWG is a particular strength as
our expectation would be that GWG in early pregnancy
would be specifically associated with outcomes and we
were able to test that here.
Table 3 Validation study: associations of maternal pre-pregnancy BMI and gestational weight gain (GWG) with MMP7
CpG sites methylation levels in newborn cord blood DNA
CpG1 CpG2 CpG3 (E59) Mean of 3 CpGs
Coefa (se) p value Coefa (se) p value Coefa (se) p value Coefa (se) p value
Pre-pregnancy BMI (n = 87) 0.80 (0.70) 0.250 1.15 (0.78) 0.143 1.22 (0.82) 0.139 1.06 (0.75) 0.158
GWG 0 to 18 wks (n = 84) 0.80 (1.99) 0.686 1.52 (2.27) 0.505 2.44 (2.36) 0.302 1.59 (2.15) 0.461
GWG 19 to 28 wks (n = 84) 0.96 (1.73) 0.580 2.89 (1.95) 0.141 2.83 (2.04) 0.167 2.23 (1.86) 0.232
GWG 29 wks. onwards (n = 84) 2.38 (1.57) 0.133 3.25 (1.79) 0.071 3.90 (1.85) 0.037 3.17 (1.69) 0.062
GWG IoM categories (n = 78)
Recommended 0 [Ref.] 0 [Ref.] 0 [Ref.] 0 [Ref.]
Less than recommended 2.03 (1.74) 0.246 0.18 (2.00) 0.930 0.38 (2.09) 0.853 0.86 (1.90) 0.649
More than recommended 3.35 (1.79) 0.063 3.13 (2.06) 0.131 3.81 (2.16) 0.080 3.43 (1.96) 0.082
aRegression coefficient using linear mixed models. For pre-pregnancy BMI (kg/m2) estimated changes per 1 SD change and for GWG estimated changes per
additional 400 g/week.
All models adjusted for child’s sex and maternal age and the inclusion of a PCR plate random batch effect.
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methylation changes were assessed in cord blood, which
limits to know how identified changes could translate to
potential target tissues. However, DNA methylation pat-
terns are largely conserved across tissues suggesting that
for population based epidemiological studies methylation
markers from easily accessible surrogate tissues could be
used as a proxy for methylation in target tissues [44]. Be-
cause cell count information was not available we cannot
rule out the potential impact of cell heterogeneity on
present findings. Secondly, limited sample size of the
discovery study population may have resulted in low
statistical power to detect true differences in DNA
methylation patterns and false positives could have oc-
curred. In addition, lack of correlation of methylation
levels in MMP7 CpG sites measured with the Golden-
Gate array and Pyrosequencing limits the conclusions
that can be drawn from the present validation and repli-
cation studies. Thirdly, smaller effect sizes in DNA
methylation were found and biological significance inTable 4 Replication study: associations of maternal pre-pregn
CpG sites methylation levels in newborn cord blood DNA (n =
CpG1 Cp
Coefa (se) p value Coefa (se)
Pre-pregnancy BMI −0.03 (0.57) 0.952 −0.44 (0.66)
GWG 0 to 18 wks. −0.34 (1.28) 0.791 −0.62 (1.46)
GWG 19 to 28 wks. −0.25 (1.45) 0.863 −1.04 (1.65)
GWG 29 wks. onwards 0.57 (1.16) 0.622 0.42 (1.33)
GWG IoM categories
Recommended 0 [Ref.] 0 [Ref.]
Less than recommended −2.00 (1.37) 0.144 −1.54 (1.56)
More than recommended −1.85 (1.39) 0.185 −2.07 (1.59)
aRegression coefficient using linear mixed models. For pre-pregnancy BMI (kg/m2) e
additional 400 g/week.
All models adjusted for child’s sex and maternal age and the inclusion of a PCR platerms of changes in gene expression is unknown. How-
ever, it may be a general phenomenon in complex
diseases and phenotypes, where methylation at any given
CpG island or specific CpG sites in affected versus
unaffected individuals may vary by less than 10%, indeed
they have been reported in many other human epigen-
etic studies. Moreover, for some genes, evidence exists
that a small change in the level of DNA methylation,
especially in the lower range, can dramatically alter gene
expression levels [45]. We opted not to consider differ-
entially methylated site below a threshold of 5% due to
the limitations inherent in interpreting biological signifi-
cance, although this cut off may have limited our find-
ings. Fourthly, the Illumina GoldenGate Panel I was
used for screening of DNA regions differently methyl-
ated in DNA cord blood. The CpG sites included in this
array are based on their functional relevance to tumor
development and cancer processes, which in only some
aspects can be related to fetal development (such as cell
proliferation). However, this array was not designed forancy BMI and gestational weight gain (GWG) with MMP7
170)
G2 CpG3 (E59) Mean of 3 CpGs
p value Coefa (se) p value Coefa (se) p value
0.501 −0.48 (0.69) 0.486 −0.31 (0.62) 0.613
0.671 −0.76 (1.55) 0.621 −0.58 (1.39) 0.674
0.528 −0.46 (1.75) 0.790 −0.60 (1.56) 0.702
0.751 0.01 (1.41) 0.994 0.34 (1.26) 0.787
0 [Ref.] 0 [Ref.]
0.323 −1.62 (1.65) 0.329 −1.71 (1.48) 0.249
0.195 −2.24 (1.68) 0.185 −2.04 (1.51) 0.177
stimated changes per 1 SD change and for GWG estimated changes per
te random batch effect.
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http://www.biomedcentral.com/1756-0500/7/278epigenome-wide analyses, and methylation changes at
other loci in genes relevant to maternal GWG may have
been overlooked. The use of the 450 k Beadchip that
offers greatly improved genomic coverage over the
GoldenGate and 27 k platforms is warranted in future
studies. Finally, we were only able to take forward the
top associated loci at MMP7 for validation and replica-
tion, which limits the interpretation of results for the
other three loci that were identified as being associated
with GWG in early pregnancy. Given the likely func-
tional relevance of these and the specificity of associ-
ation with early GWG we feel that further study of these
loci is warranted.
Conclusions
We found that greater GWG, specifically in early preg-
nancy, was associated with increased methylation at 4
CpG sites at MMP7, KCNK4, TRPM5 and NFKB1 genes
in offspring cord blood DNA. These four loci were all
potentially functionally relevant but we were only able
to take the top associated locus at MMP7 forward for
validation using Pyrosequencing and replication in non-
overlapping mother-offspring pairs. The specific associ-
ation with GWG in early pregnancy for that one site was
not statistically significantly validated and it did not repli-
cateple. Given this is the first study we are aware of to
examine these associations and our findings might reflect
limited statistical power, we advocate further exploration
of identified loci in larger studies and the study of
genome-wide DNA methylation data.
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